• Please log in or register to access this feature.

Research Article

You have full text access to this OnlineOpen article

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

  1. Gerrit Jan Wolbink1,*,
  2. Marijn Vis2,
  3. Willem Lems2,
  4. Alexandre E. Voskuyl3,
  5. Els De Groot4,
  6. Michael T. Nurmohamed5,
  7. Steven Stapel4,
  8. Paul P. Tak6,
  9. Lucien Aarden4,
  10. Ben Dijkmans3

Article first published online: 28 FEB 2006

DOI: 10.1002/art.21671

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 3, pages 711–715, March 2006

Additional Information

How to Cite

Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L. and Dijkmans, B. (2006), Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis & Rheumatism, 54: 711–715. doi: 10.1002/art.21671

Author Information

  1. 1

    CLB Sanquin Amsterdam and Jan van Breeman Institute, Amsterdam, The Netherlands

  2. 2

    Slotervaart Hospital, Amsterdam, The Netherlands

  3. 3

    VU Medical Center, Amsterdam, The Netherlands

  4. 4

    CLB Sanquin Amsterdam, Amsterdam, The Netherlands

  5. 5

    Jan van Breeman Institute, Amsterdam, The Netherlands

  6. 6

    University of Amsterdam, Amsterdam, The Netherlands

*Department of Immunopathology, CLB Sanquin Amsterdam and Department of Rheumatology, Jan van Breemen Institute Amsterdam, Dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands

Publication History

  1. Issue published online: 28 FEB 2006
  2. Article first published online: 28 FEB 2006
  3. Manuscript Accepted: 8 DEC 2005
  4. Manuscript Received: 30 JUN 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (80K)

REFERENCES

  • 1
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63.
    Direct Link:
  • 2
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051–65.
    Direct Link:
  • 3
    St.Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451–9.
    Direct Link:
  • 4
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
    Direct Link:
  • 5
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relation between serum trough infliximab levels, pre-treatment CRP levels and clinical response to infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 704–7.
  • 6
    Smolen J, Breedveld F, Burmester G, Combe B, Emery P, Kalden J, et al. Consensus statement on the initiation and continuation of TNF blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 504–5.
  • 7
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 8
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 9
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34–40.
    Direct Link:
  • 10
    Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, van Leeuwen J. IgG4 as a blocking antibody. In: HalpernGM, editor. Clinical reviews in allergy. Vol. 1. New York: Elsevier Biomedical; 1983. p. 289–302.
  • 11
    Baert F, Noman M, Vermeire S, van Assche G, d' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8.
  • 12
    LoBuglio A, Wheeler R, Trang J, Haynes A, Rogers K, Harvey EB, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989; 86: 4220–4.
View Full Article (HTML) Get PDF (80K)